ArticleCureus2025
Uncovering a Novel Homozygous MSH6 Variant in a Child Presenting With Glioblastoma: A Case of Constitutional Mismatch Repair Deficiency.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Constitutional mismatch repair deficiency (CMMRD) is a rare autosomal recessive cancer predisposition syndrome caused by biallelic mutations in mismatch repair (MMR) genes. We report a previously healthy seven-year-old boy who presented with a high-grade glioma and was later diagnosed with T-lymphoblastic lymphoma (TLL). Immunohistochemistry (IHC) of the brain tumor showed partial loss of MSH6 expression in both tumor and adjacent normal cells. Genetic testing identified a homozygous MSH6 variant (c.3680T>G, p.Ile1227Arg), with both parents confirmed as heterozygous carriers. This variant has not previously been reported in the homozygous state with clear clinical correlation. The combined clinical, histologic, and genetic findings strongly support a diagnosis of CMMRD and fulfill multiple American College of Medical Genetics and Genomics (ACMG) criteria, supporting reclassification of this variant as likely pathogenic. This case is notable for providing one of the few documented homozygous MSH6 mutations with a well-defined childhood CMMRD phenotype. It underscores the importance of integrating clinical, radiologic, histologic, and genetic evidence for accurate diagnosis, guiding surveillance, treatment, and family counseling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.